Nitric oxide-releasing phosphodiesterase type 5 inhibitors
NO-PDE5 inhibitors address the limitations of current treatments by combining NO-releasing molecules with PDE5 inhibitors to achieve sustained intraocular pressure reduction, providing enhanced efficacy and reduced side effects for conditions like glaucoma and ocular hypertension.
Patent Information
- Application Number
- JP2021506326
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-04
- Filing Date
- 2019-07-31
- Publication Date
- 2024-12-09
- Estimated Expiration
- 2039-07-31
AI Technical Summary
Current treatments for ocular hypertension and glaucoma, such as prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors, are associated with significant side effects, and nitric oxide (NO) donor compounds face challenges in delivering sustained NO release over time due to rapid degradation, leading to undesirable effects and the need for frequent administration.
Development of nitric oxide-releasing phosphodiesterase type 5 (NO-PDE5) inhibitors, which combine NO-releasing molecules with PDE5 inhibitors to provide sustained efficacy by enhancing the production of cyclic guanosine monophosphate (cGMP), thereby reducing intraocular pressure effectively.
The NO-PDE5 inhibitors demonstrate higher maximum intraocular pressure lowering effect (E_max) and longer duration compared to individual PDE5 or NO-donor compounds, offering a more effective and prolonged treatment for conditions like glaucoma and ocular hypertension with reduced side effects.
Smart Images

Figure 0007596257000001 
Figure 0007596257000002 
Figure 0007596257000003
Abstract
Description
[Technical field]
[0001] The present invention relates to nitric oxide-releasing phosphodiesterase type 5 (PDE5) inhibitors. The present invention further provides compositions and methods for treating ocular conditions associated with elevated intraocular pressure, such as ocular hypertension and glaucoma.
[0002] Glaucoma is a progressive disease that causes damage to the optic nerve and ultimately leads to complete loss of vision. Because there is a good correlation between intraocular pressure control and prevention / reduction of glaucomatous damage in patients with POAG (primary open angle glaucoma), several therapeutic drugs have been developed to treat ocular hypertension (Heijl A. et al. Arch Ophthalmol. 2002; 120: 1268-1279; Garway Heath et al. The Lancet 2015; 385: 1295-1304; Heijl A. The Lancet 2015; 385: 1264-1266).
[0003] It is known that elevated intraocular pressure can be controlled, at least in part, by administering either drugs that increase the outflow of aqueous humor from the eye, such as prostaglandin analogues (such as latanoprost or bimatoprost), or drugs that decrease the production of aqueous humor within the eye, such as beta-blockers (such as timolol, betaxolol, levobunolol) and carbonic anhydrase inhibitors (such as acetazolamide, dorzolamide or brinzolamide).
[0004] Unfortunately, many of the drugs that have been used to treat ocular hypertension have a variety of side effects. For example, prostaglandin therapy causes eye irritation and redness of various severity and duration. Beta-blockers show severe pulmonary side effects, depression, fatigue, confusion, impotence, hair loss, heart failure, and bradycardia. Side effects associated with carbonic anhydrase inhibitors include fatigue, anorexia, depression, paresthesia, and serum electrolyte abnormalities.
[0005] Nitric oxide (NO) is known to play an important role in many physiological processes; in the eye in particular, NO plays an important role in physiological intraocular pressure regulation by promoting the outflow of aqueous humor through the trabecular meshwork and Schlemm's canal (Cavet et al., Invest Ophthalmol Vis Sci. 2014, 5005-5015).
[0006] Several studies have demonstrated that NO donors reduce intraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork and Schlemm's canal.
[0007] At the cellular level, nitric oxide binds to the soluble guanylate cyclase enzyme (sGC) and increases the production of cyclic guanosine monophosphate (cGMP) in the trabecular meshwork and Schlemm's canal tissue, where it activates a series of mechanisms that promote conventional aqueous humor drainage and ultimately reduce intraocular pressure (Cavet et al., Invest Ophthalmol Vis Sci. 2014, 5005-5015).
[0008] For example, US Pat. No. 4,590,207 discloses eye drops containing isosorbide mononitrate as an active ingredient for treating and / or preventing ocular hypertension and glaucoma.
[0009] European Patent No. 2 993 172 B1 discloses nitric oxide releasing carnosine analogs for use in the treatment and / or prevention of glaucoma and ocular hypertension. Results of studies in animal models have shown that the nitric oxide releasing carnosine analogs have a higher IOP lowering effect than isosorbide mononitrate (5-ISMN), and the IOP lowering effect lasts for up to about 2 hours after topical administration.
[0010] WO 2014 / 063923 discloses nitric oxide donor compounds having a quinone-based structure and their use in the treatment and / or prevention of glaucoma and ocular hypertension.
[0011] However, in general, NO donor compounds that do not require activation by endogenous enzymes usually release nitric oxide rapidly, and as a result of the rapid release rate of nitric oxide, it is difficult to deliver sufficient amounts of NO to target tissues over an extended period of time.
[0012] One possible method to provide sustained efficacy would require multiple administrations of NO donor compounds. However, this method of treatment imposes a burden of side effects on the patient, which may be higher than a single ocular administration schedule. Excessive NO can induce undesirable effects, including oxidative stress and biosynthesis of inflammatory markers (Colasanti & Suzuki, Trends Pharmacol Sci. 2000 21:249-252).
[0013] Another possible way to provide sustained activity over a long period of time is by reducing the breakdown of cyclic guanosine monophosphate (cGMP) using phosphodiesterase type 5 (PDE5) inhibitors.
[0014] Prior art suggests the use of a combination of cyclic phosphodiesterase type 5 (PDE5) inhibitor and nitric oxide (NO) donor to treat glaucoma or ocular hypertension.For example, US Patent Publication No. 2002 / 0168424 discloses a topical drug for treating glaucoma, which comprises a mixture of a nitric oxide (NO) donor, such as nitrovasodilator minoxidil, nitroglycerin, L-arginine, isosorbide dinitrate or nitroprusside, and a phosphodiesterase type 5 (PDE5) inhibitor, such as sildenafil citrate.This combination increases blood circulation to the optic nerve and has an ocular hypotensive effect.
[0015] US Patent Publication No. 2002 / 0168424 does not disclose any experimental data relating to the intraocular pressure lowering activity of this combination, nor does it suggest effective doses of the individual compounds used.
[0016] WO 2017 / 085056 discloses dual pharmacological NO-releasing PDE5 inhibitors that are effective in the treatment of a variety of diseases in which an imbalance in cGMP occurs and / or in which PDE inhibition is believed to be beneficial, particularly in the treatment of diabetic patients, with glaucoma being cited among a long list of preferred diseases.
[0017] In this dual pharmacological NO-releasing PDE5 inhibitor, the nitric oxide precursor is a nitrooxy group (ONO2) (nitrate ester) linked directly to the hydroxyl group of the PDE5 inhibitor molecule.
[0018] WO 2017 / 085056 discloses an in vitro study on rat aortic rings showing that NO-releasing PDE5 inhibitors can activate soluble guanylate cyclase and have higher PDE5 inhibitory activity than the known PDE5 inhibitor sildenafil. However, WO 2017 / 085056 does not disclose any experimental data related to the intraocular pressure-reducing activity of NO-releasing PDE5 inhibitors.
[0019] With regard to phosphodiesterase type 5 (PDE5) inhibitors, the prior art also suggests for this class of compounds their potential therapeutic use in the treatment of glaucoma, for example:
[0020] US Pat. No. 4,975,428 discloses the use of the PDE inhibitor bemarinone as a drug for reducing intraocular pressure.
[0021] WO 01 / 60825 discloses a series of pyrazolo[4,3-d]pyrimidin-7-one derivatives as PDE5 inhibitors and lists glaucoma as one of the possible therapeutic uses of these compounds.
[0022] European Patent No. 0 463 756 discloses a series of pyrazolo[4,3-d]pyrimidin-7-one derivatives as PDE5 inhibitors as anti-angiopathy agents and lists glaucoma among the many possible therapeutic applications of these compounds.
[0023] EP 1 074 258 discloses a method for treating chronic glaucoma, chronic (idiopathic) open-angle glaucoma and glaucomatous optic neuropathy associated with macular (dry) degeneration by systemic (oral or parenteral) administration of a PDE5 inhibitor, in particular sildenafil citrate.
[0024] Thus, there is a continuing need for compounds for use in the therapeutic treatment of ocular diseases associated with elevated intraocular pressure.
[0025] The present invention provides novel nitric oxide-releasing phosphodiesterase type 5 (NO-PDE5) inhibitors in which a nitric oxide precursor is a NO-releasing molecule (NO donor) linked to a PDE5 inhibitor via an enzyme-cleavable bond.
[0026] The nitric oxide-releasing phosphodiesterase type 5 (NO-PDE5) inhibitors of the present invention have the same effects as the larger E observed with NO-PDE5 and NO-donors, respectively. max (defined as the maximum intraocular depressant effect at a given dose) and E 480分 As evidenced by the IOP reduction at the last time point analyzed, the nitric oxide releasing phosphodiesterase type 5 (NO-PDE5) inhibitors of the present invention showed better efficacy and longer duration compared to either PDE5 or NO-donors, respectively. Therefore, the nitric oxide releasing phosphodiesterase type 5 (NO-PDE5) inhibitors of the present invention are expected to provide an alternative treatment for various diseases and conditions in which reduction of intraocular pressure is desired (e.g., glaucoma, ocular hypertension, and other conditions associated with elevated intraocular pressure).
[0027] The present invention relates to a compound of formula (I): [ka] (In the formula, R1 has the following formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q-CH2-ONO2 (In the formula, y is 1 or 0; p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10, preferably, m is an integer from 1 to 6; n is an integer of 1 to 6, and preferably, n is 1 or 2. is a residue of a nitric oxide releasing molecule having the formula: R2 is ethyl or n-propyl; R3 is methyl or ethyl (wherein, when R2 is ethyl, R3 is methyl, or when R2 is n-propyl, R3 is ethyl) The present invention provides a compound of the formula:
[0028] When y=0, R1 is preferably [ka] is selected from the group consisting of:
[0029] When y=1, R1 is preferably [ka] is selected from the group consisting of:
[0030] Another embodiment of the present invention is R1 has the formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 (In the formula, y is 1 or 0, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10, preferably from 1 to 6. n is an integer of 1 to 6, and preferably, n is 1 or 2. is a residue of a nitric oxide releasing molecule having the formula: Provided is a compound of formula (I) as defined above, a stereoisomer or a salt thereof, wherein R2 is n-propyl and R3 is ethyl.
[0031] When y=0, R1 is preferably [ka] is selected from the group consisting of:
[0032] When y=1, R1 is preferably [ka] is selected from the group consisting of:
[0033] Another embodiment of the present invention is R2 is n-propyl and R3 is ethyl; R1 has the formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 is a residue of a nitric oxide releasing molecule having the formula: y=0, and R1 is [ka] The present invention provides a compound of formula (I) as defined above, a stereoisomer or a salt thereof, selected from the group consisting of:
[0034] Another embodiment of the present invention is R2 is n-propyl and R3 is ethyl; R1 has the formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 is a residue of a nitric oxide releasing molecule having the formula: y=1, and R1 is [ka] The present invention provides a compound of formula (I) as defined above, a stereoisomer or a salt thereof, selected from the group consisting of:
[0035] Another embodiment of the present invention is R1 has the formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 (In the formula, y is 1 or 0, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10, preferably, m is an integer from 1 to 6; n is an integer of 1 to 6, and preferably, n is 1 or 2. is a residue of a nitric oxide releasing molecule having the formula: Provided is a compound of formula (I) as defined above, a stereoisomer or a salt thereof, wherein R2 is ethyl and R3 is methyl.
[0036] When y=0, R1 is preferably [ka] is selected from the group consisting of:
[0037] When y=1, R1 is preferably [ka] is selected from the group consisting of:
[0038] Another embodiment of the present invention is R2 is ethyl and R3 is methyl; R1 is a residue of a nitric oxide releasing molecule having the formula: y=0, and R1 is [ka] The present invention provides a compound of formula (I) as defined above, a stereoisomer or a salt thereof, selected from the group consisting of:
[0039] Another embodiment of the present invention is R2 is ethyl and R3 is methyl; R1 is a residue of a nitric oxide releasing molecule having the formula: y=1, and R1 is [ka] The present invention provides a compound of formula (I) as defined above, a stereoisomer or a salt thereof, selected from the group consisting of:
[0040] Another embodiment of the present invention is a compound of formula (II) [ka] (In the formula, R1 has the following formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 (In the formula, y is 1 or 0, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10; preferably, m is an integer from 1 to 6; n is an integer from 1 to 6; preferably, n is 1 or 2; When y=0, R1 is preferably [ka] (selected from the group consisting of (which is the residue of a nitric oxide-releasing molecule having the formula The present invention provides a compound of the formula:
[0041] When y=1, R1 is preferably [ka] is selected from the group consisting of:
[0042] Another embodiment of the present invention is R1 has the formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 (In the formula, y=0, and R1 is [ka] (selected from the group consisting of The present invention provides a compound of formula (II) as defined above, a stereoisomer or a salt thereof, which is a residue of a nitric oxide releasing molecule having the formula:
[0043] Another embodiment of the present invention is R1 has the formula: R1 = -C(O)-(O-CH2) y (CH2)m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 (In the formula, y=1, and R1 is [ka] (selected from the group consisting of The present invention provides a compound of formula (II) as defined above, a stereoisomer or a salt thereof, which is a residue of a nitric oxide releasing molecule having the formula:
[0044] Another embodiment of the present invention is a compound of formula (Ib) having the following formula: [ka] (In the formula, R1 has the following formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 (In the formula, y is 1 or 0, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10, preferably, m is an integer from 1 to 6; n is an integer of 1 to 6, and preferably, n is 1 or 2. is a residue of a nitric oxide releasing molecule having the formula: R2 is ethyl or n-propyl; R3 is methyl or ethyl with the proviso that when R2 is ethyl, R3 is methyl, and when R2 is n-propyl, R3 is ethyl; and When R2 is ethyl and R3 is methyl, y is 0, p and q are 0, then m is not 2. The present invention provides a compound, stereoisomer or salt of the formula:
[0045] When y is 0, preferred compounds of formula (Ib) are those in which R1 is a group represented by the formulae (IIIa) to (IIIh): [ka] The group consisting of the following radicals is selected:
[0046] When y is 1, preferred compounds of formula (Ib) are those in which R1 is a group represented by the formulae (IVa) to (IVh): [ka] The group consisting of the following radicals is selected:
[0047] Another embodiment of the present invention provides a compound of formula (Ib) as defined above, a stereoisomer or a salt thereof, wherein R1, y, p, q, m and n are as defined above, R2 is ethyl and R3 is methyl.
[0048] Another embodiment of the present invention is a compound of formula (Ib) [ka] (In the formula, R1 has the formula: R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 (In the formula, y is 1, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10, preferably, m is an integer from 1 to 6; n is an integer of 1 to 6, and preferably, n is 1 or 2. is a residue of a nitric oxide releasing molecule having the formula: R2 is ethyl or n-propyl; R3 is methyl or ethyl (wherein, when R2 is ethyl, R3 is methyl; when R2 is n-propyl, R3 is ethyl) The present invention provides a compound of the formula:
[0049] Another embodiment of the present invention provides a compound of formula (Ib) as defined above, wherein p, q, m, n are as defined above, R2 is ethyl, R3 is methyl and R1 is selected from the group consisting of the groups of formulae (IIIa) to (IIIh) as defined above, a stereoisomer or a salt thereof.
[0050] Another embodiment of the present invention provides a compound of formula (Ib) as defined above, wherein p, q, m, n are as defined above, R2 is ethyl, R3 is methyl and R1 is selected from the group consisting of the groups of formulae (IVa)-(IVb) as defined above, a stereoisomer or a salt thereof.
[0051] Another embodiment of the present invention provides a compound of formula (Ib) as defined above, a stereoisomer or a salt thereof, wherein R1, y, p, q, m and n are as defined above, R2 is n-propyl and R3 is ethyl.
[0052] Another embodiment of the present invention provides a compound of formula (Ib) as defined above, wherein p, q, m, n are as defined above, R2 is n-propyl, R3 is ethyl and R1 is selected from the group consisting of the groups of formulae (IIIa) to (IIIh) as defined above, a stereoisomer or a salt thereof.
[0053] Another embodiment of the present invention provides a compound of formula (Ib) as defined above, wherein p, q, m, n are as defined above, R2 is n-propyl, R3 is ethyl and R1 is selected from the group consisting of the groups of formulae (IVa) to (IVh) as defined above, a stereoisomer or a salt thereof.
[0054] Another embodiment of the present invention is 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 3-[2,3-bis(nitrooxy)propoxy]propanoate (compound (1)) [ka] 2-(4-((3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl)sulfonyl)piperazin-1-yl)ethyl 2-(2-(nitrooxy)ethoxy)acetate (compound (2)) [ka] 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 5,6-bis(nitrooxy)hexanoate (compound (3)) [ka] 2-(4-((3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl)sulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexanoate (compound (4)) [ka] 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexyl carbonate (compound (5)) [ka] 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 5,6-bis(nitrooxy)hexyl carbonate (compound (6)) [ka] 2-{4-[4-ethoxy-3-(5-methyl-4-oxo-7-propyl-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-2-yl)benzene-1-sulfonyl]piperazin-1-yl}ethyl 5,6-bis(nitrooxy)hexanoate (compound (7)) [ka] 2-{4-[4-ethoxy-3-(5-methyl-4-oxo-7-propyl-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-2-yl)benzene-1-sulfonyl]piperazin-1-yl}ethyl 6-(nitrooxy)hexanoate (compound (8)) [ka] 2-{4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzene-1-sulfonyl]piperazin-1-yl}ethyl 5,6-bis(nitrooxy)hexanoate (compound (7b)) [ka] 2-{4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzene-1-sulfonyl]piperazin-1-yl}ethyl 6-(nitrooxy)hexanoate (compound (8b)) [ka] 2-{4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzene-1-sulfonyl]piperazin-1-yl}ethyl 3-[2,3-bis(nitrooxy)propoxy]propanoate (Compound 15) [ka] or a stereoisomer or a pharma- ceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:
[0055] Another embodiment of the present invention is a compound of formula (II) (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate (compound (9)) [ka] [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 5,6-bis(nitrooxy)hexanoate (compound (10)) [ka] (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 2-(2-(nitrooxy)ethoxy)acetate (compound (11)) [ka] [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 3-[2,3-bis(nitrooxy)propoxy]propanoate (compound (12)) [ka] (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexyl carbonate (compound (13)) [ka] ((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 5,6-bis(nitrooxy)hexyl carbonate (compound (14)) [ka] or a stereoisomer or a pharma- ceutically acceptable salt thereof.
[0056] Another embodiment of the present invention is [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl (5S)-5,6-bis(nitrooxy)hexanoate (compound (10)-(5S)); [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate (compound (12)-(2S)); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate 2-hydroxypropane-1,2,3-tricarboxylate (citrate salt of compound (9)); (S)-((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (5S)-5,6-bis(nitrooxy)hexanoate 2-hydroxypropane-1,2,3-tricarboxylate (citrate salt of compound (10)-(5S)); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 2-(2-(nitrooxy)ethoxy)acetate 2-hydroxypropane-1,2,3-tricarboxylate (compound (11) citrate salt); ((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 3-((S)-2,3-bis(nitrooxy)propoxy)propanoate) 2-hydroxypropane-1,2,3-tricarboxylate (citrate salt of compound (12)-(2S)); (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 3-[2,3-bis(nitrooxy)propoxy]propanoate citrate (citrate of compound (1)-(2S)); 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexanoate citrate (citrate of compound (4)); 2-Hydroxypropane-1,2,3-tricarboxylic acid 2-{4-[3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxybenzene-1-sulfonyl]piperazin-1-yl}ethyl [2-(nitrooxy)ethoxy]acetate (citrate salt of compound (2)); (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 5,6-bis(nitrooxy)hexanoate citrate (citrate of compound (3)-(5S)); (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl) ethyl 3-(2,3-bis(nitrooxy)propoxy)propanoate dihydrochloride (hydrochloride of compound (1)-(2S)); ((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (S)-5,6-bis(nitrooxy)hexyl carbonate (compound (14)-(5S)); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexyl carbonate 2-hydroxypropane-1,2,3-tricarboxylate (citrate salt of compound (13)); (S)-2-(4-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl (S)-5,6-bis(nitrooxy)hexanoate (compound (7b)-(5S)); (S)-2-(4-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl (S)-3-(2,3-bis(nitrooxy)propoxy)propanoate (compound (15), (S) isomer); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate fumarate (fumaric acid salt of compound (9)); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate maleate (maleate of compound (9)) The present invention provides a compound of formula (I), (Ib) or (II) selected from the group consisting of:
[0057] Another embodiment of the present invention provides a compound of Formula (I), or Formula (Ib), or Formula (II), or a pharma- ceutically acceptable salt thereof, for use in a method of treating a disease or condition associated with elevated intraocular pressure, preferably the disease or condition is selected from ocular hypertension or glaucoma, including open-angle, normal tension, pigmentary or pseudoexfoliative glaucoma or drug-induced glaucoma.
[0058] Another embodiment of the invention provides a compound of Formula (I), or Formula (Ib), or Formula (II), or a pharma- ceutically acceptable salt thereof, for use in a method of treating retinopathy, including retinopathy of prematurity, retinal vein occlusion, or diabetic macular edema.
[0059] Another embodiment of the present invention provides an ophthalmic pharmaceutical composition comprising a compound of Formula (I), or Formula (Ib), or Formula (II), or a stereoisomer or pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient and / or vehicle, the ophthalmic pharmaceutical composition being in the form of a solution, suspension, gel, cream, or emulsion.
[0060] Certain compounds of the present invention can be converted into acid salts.Therefore, compounds of the present invention can exist as salts.Examples of such salts are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.; or organic acids such as acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, malonic acid, fumaric acid, maleic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, citric acid, methylsulfonic acid, ethanesulfonic acid, benzenesulfonic acid, formic acid, etc.
[0061] The individual enantiomers of the compounds of formula (I), formula (II), or formula (Ib), as well as diastereoisomers, racemic and non-racemic mixtures thereof, are within the scope of the present invention.
[0062] Another embodiment of the invention is a combination of a compound of formula (I), or of formula (Ib), or of formula (II), and a drug of the following classes: beta-adrenergic antagonists selected from carteolol, levobunolol, metipranolol or timolol; a prostaglandin analogue selected from latanoprost, travoprost, tafluprost or bimatoprost, or their respective NO-donating derivatives; Adrenergic agonists selected from epinephrine borate, epinephrine hydrochloride, dipivefrin or apraclonidine; a carbonic anhydrase inhibitor selected from acetazolamide, dichlorphenamide, methazolamide, brinzolamide or dorzolamide; A cholinergic agonist selected from carbachol, pilocarpine hydrochloride, pilocarpine nitrate or pilocarpine; A steroid selected from fluocinolone, fluticasone propionate, triamcinolone or dexamethasone; A cholinesterase inhibitor selected from demecarium, echothiophate or physostigmine; a soluble guanylate cyclase activator (sCG activator), preferably the sCG activator is a compound disclosed in WO 2016 / 001875, more preferably the sCG activator is (+)-1-(6-(3-((4-(1-(cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1H-inden-4-yl)pyridin-2-yl)-5-methyl-1H-pyrazole-4-carboxylic acid (MGV-354) disclosed in WO 2016 / 001875; Rho-kinase inhibitors, including netarsudil, ripasudil, fasudil, belosudil, (+)-(R)-trans-4-(l-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride (Y-27632) or (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide (Y-39383) as disclosed in U.S. Patent Publication No. 2012 / 0288428; sGC activator Cinaciguat The present invention relates to a composition comprising at least one additional active agent selected from the group consisting of:
[0063] The above-mentioned compositions comprising a compound of formula (I), or a compound of formula (Ib), or a compound of formula (II), and at least one other active drug selected from beta-adrenergic antagonists, prostaglandin analogues, adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, steroids, cholinesterase inhibitors, soluble guanylate cyclase activators or Rho-kinase inhibitors, may be prepared in one dosage form containing the two active compounds in a suitable mixing ratio, or may be prepared as a kit for simultaneous or separate administration of the two active compounds prepared in separate dosage forms.
[0064] Another embodiment of the present invention is a topical ophthalmic dosage form comprising a compound of formula (I), or a compound of formula (Ib), or a compound of formula (II) or a salt thereof, and a drug of the following classes: Prostaglandin analogues, beta-adrenergic antagonists, carbonic anhydrase inhibitors, cholinergic agonists, steroids, cholinesterase inhibitors, soluble guanylate cyclase activators or Rho-kinase inhibitors or sGC activators cinaciguat The present invention provides a composition that is a kit containing another topical ocular dosage form comprising an active agent selected from the group consisting of:
[0065] Another embodiment provides the use of a composition comprising a compound of formula (I), or a compound of formula (Ib), or a compound of formula (II), and at least one other active agent as reported above, for use in a method for treating a disease or condition associated with elevated intraocular pressure. Preferably, said disease or condition is selected from ocular hypertension or glaucoma, including open-angle glaucoma, normal tension glaucoma, pigmentary glaucoma, pseudoexfoliation glaucoma or drug-induced glaucoma.
[0066] Another embodiment provides the use of a composition comprising a compound of formula (I), or a compound of formula (Ib), or a compound of formula (II), and at least one further active agent as reported above, for use in a method for treating retinopathy, including retinopathy of prematurity, retinal vein occlusion, or diabetic macular edema.
[0067] In compositions for topical administration, the concentration of the compound of the present invention is generally 0.0001% to 3% (weight / volume) or 0.003% to 3% (weight / volume), preferably 0.03% to 2% (weight / volume), and most preferably 0.3% to 1% (weight / volume).
[0068] Another embodiment of the present invention provides 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid (compound (IIIg)-OH) or 6-(nitrooxy)hexanoic acid (compound (IIIa)-OH) for use as an intraocular pressure-reducing agent for treating an ocular disease or condition associated with elevated intraocular pressure.
[0069] Another embodiment of the present invention provides 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid (compound (IIIg)-OH) or 6-(nitrooxy)hexanoic acid (compound (IIIa)-OH) for use in a method for treating retinopathy, including retinopathy of prematurity, retinal vein occlusion or diabetic macular edema.
[0070] Another embodiment of the present invention provides an ophthalmic composition comprising the compound 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid ((IIIg)-OH) or the compound 6-(nitrooxy)hexanoic acid ((IIIa)-OH) and a pharma- ceutically acceptable excipient and / or vehicle.
[0071] Another embodiment of the present invention is a method for treating a patient suffering from atopic dermatitis, comprising administering to a patient a drug of the following class: Beta-adrenergic antagonists, prostaglandin analogues, adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, steroids, cholinesterase inhibitors, soluble guanylate cyclase activators, Rho-kinase inhibitors, or cinaciguat The present invention provides an ophthalmic composition comprising at least one additional active agent selected from the group consisting of:
[0072] The composition may be prepared in one dosage form containing the two active compounds in a suitable mixing ratio, or as a kit for simultaneous or separate administration of the two active compounds prepared in separate dosage forms.
[0073] general synthesis Formula (I) and Formula (II) [ka] (In the formula, R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2, y=0, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10, preferably, m is an integer from 1 to 6; n is an integer from 1 to 6, preferably n is 1 or 2; R2 is n-propyl and R3 is ethyl, or R2 is ethyl and R3 is methyl. The compound of formula A1, A2 or A3 [ka] with a compound of formula B1: HO-C(O)-(CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 B1 (wherein p, q, m and n are as defined above). with a compound of the formula: The reaction is carried out in aprotic polar / non-polar solvents such as THF, DMF or CHCl in the presence of varying amounts of DMAP and coupling agents such as N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) or 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) at temperatures ranging from -0°C to 80°C.
[0074] Alternatively, the compound of formula (I) can be prepared by reacting a compound of formula A1, formula A2 or formula A3 with a compound of formula (B2): XC(O)-(CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 B2 where p, q, m and n are as defined above and X is -Cl, p-nitrophenoxy, pentafluorophenoxy or 2,5-pyrrolidinedione, 1-oxy. with a compound of the formula: When X=-Cl, the reaction is carried out in aprotic / non-polar solvents such as THF, DMF or CH2Cl2 in the presence of a base such as DMAP, pyridine or triethylamine or K2CO3, Cs2CO3 at a temperature range of -20°C to 60°C.
[0075] When X is selected from p-nitrophenoxy, pentafluorophenoxy or 2,5-pyrrolidinedione, 1-oxy, the reaction is carried out in the presence of DMAP with or without a catalyst such as scandium triflate at a temperature ranging from 0° C. to 80° C. in an aprotic polar / non-polar solvent such as THF, DMF or CH2Cl2.
[0076] Compound A1 is known in the literature as mirodenafil. Compounds A1 and A2 are disclosed in U.S. Patent No. 6,962,911. Compound A3 is known in the literature as avanafil and its synthesis is disclosed in US Pat. No. 6,656,935.
[0077] Compounds of formula B2 are generally prepared from compound B1 using methods known in the literature.
[0078] Compound B1 is known in the art or can be prepared by known methods from known compounds: For example, compound B1 can be prepared according to formula B3: HO-CH2-(CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2- ONO2 B3 (wherein m, n, p and q are as defined above). can be prepared from the corresponding alcohol of the formula: by oxidation with known reagents such as 2,2,6,6-tetramethylpiperidinyloxyl (TEMPO) or ruthenium(IV) oxide / sodium periodate.
[0079] Examples of the synthesis of compound (B1) are described in WO 2009 / 098113 or WO 2016 / 155906.
[0080] Formula (I) and Formula (II): [ka] (In the formula, R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2, y=1, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10, preferably, m is an integer from 1 to 6; n is an integer from 1 to 6; preferably, n is 1 or 2; R2 is n-propyl and R3 is ethyl, or R2 is ethyl and R3 is methyl. The compounds of formula A4, A5 or A6 [ka] with one or more equivalents of a compound of formula B3 HO-CH2(CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2- ONO2 B3 (wherein p, q, and n are as defined above). in the presence of an organic or inorganic base such as DMAP, TEA, DIPEA, etc., with or without a catalyst such as Sc(OTf)3, in an aprotic polar / non-polar solvent such as THF, DMF, CH2Cl2, etc., at temperatures ranging from -20°C to 100°C, according to methods well known in the literature.
[0081] Compounds of formula A4, A5 and A6 are prepared from compounds A1, A2 and A3, respectively, by methods known in the art.
[0082] Alternatively, compounds (I) and (II) can be prepared by reacting compounds A1, A2 or A3 with a compound of formula B4 pNO2-C6H4-C(O)-O-CH2-(CH2) m -[O-(CH2) n ] p - (CH-ONO2) q -CH2-ONO2 B4 (wherein p, q, and n are as defined above). in the presence of an organic or inorganic base such as DMAP, TEA, DIPEA, etc., with or without a catalyst such as Sc(OTf)3, in an aprotic polar / non-polar solvent such as THF, DMF, CH2Cl2, etc., at temperatures ranging from -20°C to 100°C, according to methods well known in the literature.
[0083] Compounds of formula B4 can be readily prepared from compound B3 by methods known in the art.
[0084] Formula (Ib) [ka] (In the formula, R1 = -C(O)-(O-CH2) y (CH2) m -[O-(CH2) n ] p -(CH- ONO2) q -CH2-ONO2, y=0, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10; n is an integer from 1 to 6, R2 is n-propyl and R3 is ethyl, or R2 is ethyl and R3 is methyl. The compounds of formula A1b, A2b [ka] The compound of formula B1 HO-C(O)-(CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2-ONO2 B1 (wherein p, q, m and n are as defined above). with a compound of the formula: The reaction is carried out in aprotic polar / non-polar solvents such as THF, DMF or CHCl in the presence of varying amounts of DMAP in the presence of coupling agents such as N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) or 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate (HATU) at temperatures ranging from -0°C to 80°C.
[0085] Alternatively, the compound of formula (Ib) can be prepared by reacting a compound of formula A1b or formula A2b with a compound of formula B2: XC(O)-(CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2- ONO2 B2 where p, q, m and n are as defined above and X is -Cl, p-nitrophenoxy, pentafluorophenoxy or 2,5-pyrrolidinedione, 1-oxy. with a compound of the formula: When X=-Cl, the reaction is carried out in an aprotic / non-polar solvent such as THF, DMF or CH2Cl2 at temperatures ranging from -20°C to 60°C in the presence of a base such as DMAP, pyridine or triethylamine or K2CO3, Cs2CO3.
[0086] When X is p-nitrophenoxy, pentafluorophenoxy or 2,5-pyrrolidinedione, 1-oxy, the reaction is carried out in the presence of DMAP in an aprotic polar / non-polar solvent such as THF, DMF or CH2Cl2, with or without a catalyst such as scandium triflate, at a temperature ranging from 0°C to 80°C.
[0087] Compounds A1b and A2b are disclosed in European Patent No. 0 463 756. A2b is known as lodenafil.
[0088] Compounds of formula B2 are either known in the literature or are generally prepared from compound B1 using methods known in the literature.
[0089] Compound B1 is known in the art or can be prepared by known methods from known compounds: for example, compound B1 can be represented by the formula B3 HO-CH2-(CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2- ONO2 B3 (wherein m, n, p and q are as defined above). can be prepared from the corresponding alcohol of the formula: by oxidation using known reagents such as 2,2,6,6-tetramethylpiperidinyloxyl (TEMPO) or ruthenium(IV) oxide / sodium periodate.
[0090] Synthesis examples of compound (B1) are described in WO 2009 / 098113 or WO 2016 / 155906.
[0091] Formula (Ib) [ka] (In the formula, R1 = -C(O)-(O-CH2) y (CH2)m -[O-(CH2) n ] p -(CH- ONO2) q -CH2-ONO2, y=1, p is 1 or 0; q is 1 or 0; m is an integer from 1 to 10; n is an integer from 1 to 6, R2 is n-propyl and R3 is ethyl (A5b) or R2 is ethyl and R3 is methyl (A4b) The compound of formula A4b or A5b [ka] with one or more equivalents of a compound of formula B3 HO-CH2-(CH2) m -[O-(CH2) n ] p -(CH-ONO2) q -CH2- ONO2 B3 (wherein m, p, q and n are as defined above). can generally be prepared by reacting a compound of formula (I) with the compound of formula (I) in the presence of an organic or inorganic base such as DMAP, TEA, DIPEA, etc., in an aprotic polar / non-polar solvent such as THF, DMF, CH2Cl2, etc., at temperatures ranging from -20°C to 100°C, with or without a catalyst such as Sc(OTf)3, according to methods well known in the literature.
[0092] Compounds of formula A4b and A5b are prepared from compounds A2b and A1b, respectively, by methods known in the art.
[0093] Alternatively, compound (Ib) can be prepared by reacting compound A1b or A2b with a compound of formula B4 pNO2-C6H4-C(O)-O-CH2-(CH2) m -[O-(CH2) n ] p - (CH-ONO2) q -CH2-ONO2 B4 (wherein m, p, q and n are as defined above). with aprotic polar / non-polar solvents such as THF, DMF, CH2Cl2, in the presence of organic or inorganic bases such as DMAP, TEA, DIPEA, with or without a catalyst such as Sc(OTf)3, according to methods well known in the literature, at temperatures ranging from -20°C to 100°C.
[0094] Compounds of formula B4 are prepared from compounds B3 by methods known in the art.
[0095] Glossary ACN: Acetonitrile AC2O: Acetic anhydride DCC: dicyclohexylcarbodiimide DCM: dichloromethane DIPEA: N,N-diisopropylethylamine DMF: N,N-dimethylformamide DMSO: Dimethyl sulfoxide DMAP: 4-dimethylaminopyridine EtOAc: ethyl acetate Et2O: Ethyl ether EtOH: Ethanol iPrOH: Isopropanol NBS: N-bromosuccinimide MTBE: Methyl tert-butyl ether TEA: Triethylamine TEMPO: 2,2,6,6-tetramethylpiperidine-1-oxyl THF: tetrahydrofuran PhP3: Triphenylphosphine
[0096] Example 1 (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate (compound (9)) [ka]
[0097] To a solution of avanafil (1.00 g, 2.07 mmol) in dry DCM (15 mL) was added DMAP (252 mg, 2.07 mmol), DCC (512 mg, 2.48 mmol) and 6-(nitrooxy)hexanoic acid (440 mg, 2.48 mmol).
[0098] The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous layer was extracted twice with DCM. The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.1% formic acid, 70:30 to 40:60).
[0099] The residue was taken up in DCM and the solution was washed with a saturated aqueous solution of NaHCO3. The aqueous layer was then extracted twice with DCM. The combined organic phase was dried over MgSO4 and concentrated under reduced pressure to give the desired product (compound (9)) 1.23 g (yield: 93.0%).
[0100] 1H NMR (400 MHz, DMSO-d6) δ 9.19 (s, 1H), 8.81 (m, 1H), 8.75 (d, J = 4.9 Hz, 2H), 8.54 (m, 1H), 7.50 - 7.14 (m, 3H), 7.06 (s, 1H), 4.54 (m, 4H), 4.37 - 3.90 (m, 3H), 3.81 (s, 3H), 3.59 - 3.39 (m, 4H), 2.32 (t, J = 7.1 Hz, 2H), 2.09 - 1.73 (m, 4H), 1.66 - 1.52 (m, 4H), 1.32 (dt, J = 5.2, 7.5 Hz, 2H).
[0101] Example 2 [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl (5S)-5,6-bis(nitrooxy)hexanoate (compound (10)-(5S)-isomer) [ka]
[0102] To a solution of avanafil (120 mg, 0.248 mmol) in dry DCM (1.5 mL) was added DMAP (30 mg, 0.248 mmol), DCC (56 mg, 0.273 mmol) and (5S)-5,6-bis(nitrooxy)hexanoic acid (65 mg, 0.273 mmol).
[0103] The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.01% formic acid, 70:30 to 40:60).
[0104] After purification, the residue was added with DCM and a saturated solution of NaHCO3. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure to give the desired product (compound (10)-(5S)-isomer) 165 mg (yield: 94.5%).
[0105] 1 H NMR (400 MHz, DMSO-d6) δ 9.16 (t, J = 6.0 Hz, 1H), 8.79 (m, 1H), 8.75 (d, J = 4.9 Hz, 2H), 8.54 (s, 1H), 7.38 (t, J= 4.9 Hz, 1H), 7.34 - 7.23 (m, 1H), 7.19 (d, J = 7.4 Hz, 1H), 7.05 (t, J= 9.8 Hz, 1H), 5.41 (m, 1H), 4.91 (m, 1H), 4.71 (m, 1H), 4.54 (m, 4H), 4.16 (m, 3H), 3.98 (s, 3H), 3.50 (m, 2H), 2.38 (t, J = 6.7 Hz, 2H), 1.92 (m, 4H), 1.79 - 1.51 (m, 4H).
[0106] Example 3 (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 2-(2-(nitrooxy)ethoxy)acetate (compound (11)) [ka]
[0107] To a solution of avanafil (160 mg, 0.331 mmol) in dry DCM (1.5 ml) was added DMAP (40 mg, 0.327 mmol), DCC (82 mg, 0.397 mmol) and 2-(2-(nitrooxy)ethoxy)acetic acid (82 mg, 0.497 mmol).
[0108] The mixture was stirred at room temperature over the weekend and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.01% formic acid, 90:10 to 65:35).
[0109] After purification, the residue was added with DCM and a saturated solution of NaHCO3. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure to give the desired product (compound (11)) 109 mg (yield: 52%).
[0110] 1 H NMR (400 MHz, DMSO-d6) δ 9.16 (t, J = 6.0 Hz, 1H), 8.79 (s, 1H), 8.75 (d, J = 4.9 Hz, 2H), 8.54 (s, 1H), 7.38 (t, J = 4.9 Hz, 1H), 7.24 (m, 1H), 7.06 (s, 1H), 4.70 (m, 2H), 4.54 (m, 4H), 4.26 (dd, J = 10.5, 3.4 Hz, 1H), 4.18 (s, 2H), 3.80 (s, 3H), 3.78 (m, 2H), 3.50 (m, 2H), 2.02 - 1.79 (m, 4H).
[0111] Example 4 [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate (compound (12)-(2S)-isomer) [ka]
[0112] To a solution of avanafil (160 mg, 0.331 mmol) and 4-nitrophenyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate (82 mg, 0.497 mmol) in dry DCM (1.5 mL) was added DMAP (40 mg, 0.327 mmol).
[0113] The mixture was stirred at room temperature over the weekend and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.01% formic acid, 85:15 to 55:45).
[0114] After purification, the residue was added with DCM and a saturated solution of NaHCO3. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phase was dried over MgSO4 and concentrated under reduced pressure to give the desired product (compound (12)-(2S)-isomer) 227 mg (yield: 95.0%).
[0115] 1 H NMR (400 MHz, DMSO-d6) δ 9.16 (t, J = 6.0 Hz, 1H), 8.78 (s, 1H), 8.75 (d, J = 4.9 Hz, 1H), 8.53 (s, 1H), 7.38 (t, J= 4.9 Hz, 1H), 7.34 - 7.16 (m, 1H), 7.05 (t, J = 9.4 Hz, 1H), 5.55 (q, 1H), 4.89 (d, J = 12.9 Hz, 1H), 4.75 (m, 1H), 4.54 (m, 4H), 4.41 - 3.93 (m, 3H), 3.80 (s, 3H), 3.78 - 3.63 (m, 4H), 3.51 (m, 2H), 2.57 (t, J = 6.1 Hz, 2H), 1.92 (m, 4H).
[0116] Synthesis of 4-nitrophenyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate
[0117] Step 1: Synthesis of (S)-4-(allyloxymethyl)-2,2-dimethyl-1,3-dioxolane NaH (60%) (3.4 g, 85.54 mmol) was suspended with S(+)-1,2-isopropylideneglycerol (5.65 g, 42.75 mmol) and 15-crown-5 (0.9 g, 4.28 mmol) in dry THF (140 mL).
[0118] The mixture was cooled to 0° C. and allyl bromide (7.2 mL, 85.54 mmol) was added dropwise. The suspension was stirred at room temperature for 6 h, then saturated NH4Cl solution (100 mL) was added dropwise at 0° C., and then the mixture was extracted with Et2O (3×100 mL). The combined organic layers were washed once with brine and carefully concentrated under reduced pressure. The residue was purified by flash chromatography (Biotage SP4 apparatus, SNAP 100 column, isocratic elution, Et2O / cyclohexane 1:9) to give the title compound ((S)-4-(allyloxymethyl)-2,2-dimethyl-1,3-dioxolane) 5.8 g (yield: 78.5%).
[0119] 1 H NMR (300 MHz, Chloroform-d) δ 6.00 - 5.78 (m, 1H), 5.35 - 5.13 (m, 2H), 4.35 - 4.21 (m, 1H), 4.11 - 3.98 (m, 3H), 3.73 (m, 1H), 3.57 - 3.40 (m, 2H), 1.51 - 1.32 (m, 6H).
[0120] Step 2: Synthesis of (S)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propan-1-ol
[0121] To a stirred solution of (S)-4-(allyloxymethyl)-2,2-dimethyl-1,3-dioxolane (2.0 g, 10.64 mmol) in dry THF (180 mL) cooled at 0° C. was added 9BBN 0.5 M (241.8 mL, 121 mmol) dropwise. The reaction was stirred at 0° C. for 30 min and at room temperature overnight. The reaction mixture was cooled to 0° C. and NaOH2N (84 mL) was added along with H2O2 30% (58 mL). The mixture was diluted with Et2O (100 mL) and NaOH 1N (100 mL). The two phases were separated and the aqueous layer was extracted with Et2O (3×120 mL). The combined organic layers were washed once with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (Biotage SP4 apparatus, SNAP 100 column, EtOAC in cyclohexane, (30%-80%), column volume (cv) 10) to give the title compound ((S)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propan-1-ol) 6.4 g (yield: 100%).
[0122] 1 H NMR (300 MHz, Chloroform-d) δ 4.35 - 4.20 (m, 1H), 4.11-4.01 (m, 1H), 3.85 - 3.63 (m, 5H), 3.58 - 3.46 (m, 2H), 1.97 - 1.80 (m, 2H), 1.45 (s, 3H), 1.38 (s, 3H).
[0123] Step 3: Synthesis of (S)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propanoic acid
[0124] To a solution of (S)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propan-1-ol (2.03 g, 10.51 mmol) in acetone (50 mL) cooled at 0° C. was added saturated NaHCO3 solution (56 mL), NaBr (0.45 g, 4.20 mmol) and TEMPO (0.34 g, 2.10 mmol). Then trichloroisocyanuric acid (4.91 g, 21.02 mmol) was added in portions. The mixture was allowed to reach room temperature and stirred for 3 h. Then the mixture was cooled at 0° C. and isopropanol (20 mL) was added slowly. The mixture was stirred at 0° C. for 30 min. The formation of a white solid was observed. The precipitate was filtered off and the solvent was concentrated. NaOH 2N was added to the residue (pH=12) and the aqueous solution was washed twice with EtOAc. The aqueous phase was added with HCl 1N until pH 2-3 and extracted with EtOAc (5×50 mL). The combined organic phase was dried over Na2SO4 and then evaporated to give the title compound ((S)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propanoic acid) 0.82 g (yield: 38%).
[0125] 1 HNMR (300 MHz, Chloroform-d) δ 4.34 - 4.16 (m, 1H), 4.11 -3.97 (m, 1H), 3.85 - 3.68 (m, 3H), 3.63 - 3.42 (m, 2H), 2.74 - 2.55 (m, 2H), 1.41 (s, 3H), 1.35 (s, 3H).
[0126] Step 4: Synthesis of (S)-4-nitrophenyl 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propanoate
[0127] To a solution of (S)-3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propanoic acid (0.82 g, 4.02 mmol), DCC (0.83 mg, 4.02 mmol) and DMAP (0.1 g, 0.80 mmol) in DCM (15 mL) was added 4-nitrophenol (0.56 g, 4.02 mmol) in portions. The mixture was stirred at room temperature overnight, the precipitate was filtered off and the solvent was evaporated. The residue was purified by flash chromatography (Biotage SP4 apparatus, 5% to 50% EtOAc in cyclohexane, column volume (CV) 12) to give the title compound ((S)-4-nitrophenyl 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propanoate) 0.97 g (yield: 74%).
[0128] 1 H NMR (300 MHz, Chloroform-d) δ 8.33 - 8.21 (m, 2H), 7.37 - 7.20 (m, 2H), 4.37 - 4.20 (m, 1H), 4.09 - 4.00 (m, 1H), 3.96 - 3.84 (m, 2H), 3.80 - 3.66 (m, 1H), 3.63 - 3.47 (m, 2H), 2.96 - 2.78 (m, 2H), 1.42 (s, 3H), 1.36 (s, 3H).
[0129] Step 5: Synthesis of (R)-4-nitrophenyl 3-(2,3-dihydroxypropoxy)propanoate
[0130] To a stirred solution of (S)-4-nitrophenyl 3-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)propanoate (0.97 g, 2.97 mmol) in THF (10 mL) was added HCl 3N (2 mL) and the solution was stirred at room temperature for 4 h. Then, EtOAc (5 mL) and H2O (5 mL) were added and the two phases were separated. The aqueous phase was extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give 0.89 g of the title compound ((R)-4-nitrophenyl 3-(2,3-dihydroxypropoxy)propanoate), which was used in the next step without further purification.
[0131] Step 6: Synthesis of 4-nitrophenyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate
[0132] To a solution of Ac2O (0.76 mL, 8.07 mmol) in DCM (5 mL) was added fuming nitric acid (0.38 mL, 9.32 mmol) portionwise at -40 °C. Then, a solution of (R)-4-nitrophenyl 3-(2,3-dihydroxypropoxy)propanoate (0.89 g, 3.11 mmol) in DCM (7 mL) was added dropwise. The mixture was allowed to reach 0 °C and stirred for 4 h. Then, the mixture was poured onto ice and NaHCO3 was added portionwise. The two phases were separated and the aqueous phase was washed twice with DCM. The combined organic phase was dried over Na2SO4 and concentrated to give the title compound (4-nitrophenyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate) 0.56 g (yield for two steps: 38%).
[0133] 1 H NMR (300 MHz, Chloroform-d) δ 8.35 - 8.22 (m, 2H), 7.35 - 7.22 (m, 2H), 5.48 - 5.34 (m, 1H), 4.88 - 4.73 (m, 1H), 4.73 - 4.56 (m, 1H), 3.94 - 3.85 (m, 2H), 3.85 - 3.77 (m, 2H), 2.88 (t, 2H).
[0134] Synthesis of 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid (compound (IIIg)-OH)
[0135] A solution of 4-nitrophenyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate (step 6) (500 mg, 1.33 mmol) in 5 mL of a 1 / 1 (v / v) mixture of EtOH / THF was cooled to 0° C. Then, 1.33 mL (2.66 mmol) of 2 N NaOH solution was added portionwise to the stirred solution over 45 min.
[0136] The mixture was left under stirring for 1 h. The organic solvent was then removed under vacuum and EtOAc (25 mL) and water (25 mL) were added. The organic phase was removed and the pH of the aqueous phase was brought to 1 using 2N HCl. The aqueous phase was extracted with DCM (2×15 mL), dried over sodium sulfate and evaporated under vacuum.
[0137] The raw product was purified on a 4g 25μ C18 cartridge using a gradient of (ACN) / (H2O+0.1% HCOOH) from 5 / 95 to 30 / 70 in 30 min.
[0138] Fractions containing clean product were pooled and lyophilized to give the title compound (3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid) 210 mg (yield: 61%) as a clear oil.
[0139] 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.43 - 2.48 (m, 2 H) 3.61 - 3.78 (m, 4 H) 4.76 (dd, J=12.89, 6.54 Hz, 1 H) 4.92 (dd, J=12.89, 2.93 Hz, 1 H) 5.54 - 5.59 (m, 1 H) 12.23 (br s, 1 H).
[0140] Example 5 (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate 2-hydroxypropane-1,2,3-tricarboxylate (citrate salt of compound (9)) [ka]
[0141] To a solution of compound (9) (100 mg, 0.155 mmol) prepared as described in Example 1 in methanol (1.5 mL) was added citric acid monohydrate (33 mg, 0.155 mmol). The mixture was stirred at room temperature for 10 minutes, then concentrated, and the solid was washed with MTBE. The solid was filtered and dried under reduced pressure to give the desired product (citrate salt of compound (9)) 125 mg (crude yield: 96.6%).
[0142] 1H NMR (600 MHz, DMSO-d6) δ 12.39 - 12.36 (m, 3H), 9.19 (s, 1H), 8.80 (m, 1H), 8.75 (d, J = 4.9 Hz, 2H), 8.53 (m, 1H), ), 7.42 - 7.15 (m, 3H), 7.06 (m, 1H), 4.65 - 4.38 (m, 6H), 4.37- 4.11 (m, 3H), 3.80 (s, 3H) 3.59 - 3.39 (m, 2H), 2.75 (d, J = 15.4 Hz, 2H), 2.65 (d, J = 15.4 Hz, 2H), 2.32 (m, 2H), 2.05 - 1.80 (m, 4H), 1.47 - 1.08 (m, 4H), 1.32 (q, 2H).
[0143] Example 6 ((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (5S)-5,6-bis(nitrooxy)hexanoate 2-hydroxypropane-1,2,3-tricarboxylate (compound (10)-(5S) isomer, citrate salt) [ka]
[0144] To a solution of compound (10)-(5S)-isomer (165 mg, 0.234 mmol) prepared as described in Example 2 in methanol (1.5 mL) was added citric acid monohydrate (49 mg, 0.233 mmol). The mixture was stirred at room temperature for 10 min, then concentrated and the residue was washed with diethyl ether. The solid was filtered and dried under reduced pressure to give the desired product (compound (10)-(5S) isomer-citrate salt) 205 mg (crude yield: 97.8%).
[0145] 1 H NMR (600 MHz, DMSO-d6) δ 12.37 (s, 3H), 9.18 (s, 1H), 8.85-8.70 (m, 3H), 8.53 (m, 1H), 7.42-7.36 (m, 2H), 7.34 - 7.15 (m, 1H), 7.10-7.01 (m, 1H), 5.41 (m, 1H), 4.91 (d, J = 12.4 Hz, 1H), 4.70 (m, 1H), 4.63 - 4.42 (m, 4H), 4.38-3.92 (m,3H), 3.81 (s, 3H), 3.51 (m, 2H), 2.75 (d, J = 15.4 Hz, 2H), 2.66 (d, J = 15.4 Hz, 2H), 2.38 (m, 2H), 1.92 (m, 4H), 1.79-1.58 (m, 4H).
[0146] Example 7 (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 2-(2-(nitrooxy)ethoxy)acetate 2-hydroxypropane-1,2,3-tricarboxylate (citrate salt of compound (11)) [ka]
[0147] To a solution of compound 11 (109 mg, 0.173 mmol) prepared as described in Example 3 in methanol (1.0 mL) was added citric acid monohydrate (36 mg, 0.171 mmol). The mixture was stirred at room temperature for 10 minutes, then concentrated, and the residue was washed with diethyl ether. The solid was filtered and dried under reduced pressure to give the desired product (compound (11) citrate salt) 139 mg (crude yield: 97.6%).
[0148] 1H NMR (600 MHz, DMSO-d6) δ 12.36 (s, 3H), 9.18 (s, 1H), 8.85-8.72 (m, 3H), 8.53 (m, 1H), 7.41-7.35 (m, 2H), 7.34 - 7.15 (m, 1H), 7.06 (m, 1H), 4.70 - 4.64 (m, 2H), 4.62 - 4.46 (m, 4H), 4.40 - 3.99 (m, 5H), 3.80 (s, 3H), 3.78 (m, 2H), 3.58 - 3.43 (m, 2H), 2.75 (d, J = 15.4 Hz, 2H), 2.66 (d, J = 15.4 Hz, 2H), 1.93 (m, 4H).
[0149] Example 8 ((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 3-((S)-2,3-bis(nitrooxy)propoxy)propanoate 2-hydroxypropane-1,2,3-tricarboxylate (compound (12)-(2S)-isomer, citrate salt) [ka]
[0150] To a solution of compound 12, (2S)-isomer, (227 mg, 0.315 mmol) prepared as described in Example 4 in methanol (2 mL) was added citric acid monohydrate (66 mg, 0.315 mmol). The mixture was stirred at room temperature for 10 min, then concentrated, and the residue was washed with diethyl ether. The solid was filtered and dried under reduced pressure to give the desired product (compound (12)-(2S) isomer, citrate salt) 280 mg (crude yield: 97.4%).
[0151] 1 H NMR (600 MHz, DMSO-d6) δ 12.35 (s, 3H), 9.18 (s, 1H), 8.77 (m, 2H), 8.55 (m, 1H), 7.46-7.33 (m, 1H), 7.34 - 7.17 (m, 1H), 7.06 (dd, J = 16.6, 8.3 Hz, 1H), 5.55 (s, 1H), 4.81 (m, 4H), 4.63 - 4.42 (m, 4H), 4.38 - 3.96 (m, 3H), 3.81 (s, 3H), 3.71 (m, 2H), 3.57 - 3.42 (m, 2H), 2.75 (d, J= 15.4 Hz, 2H), 2.65 (d, J = 15.4 Hz, 2H), 2.57 (t, J = 5.9 Hz, 2H), 1.92 (m, 4H).
[0152] Example 9 (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 3-[2,3-bis(nitrooxy)propoxy]propanoate citrate (Compound (1)-(2S)-isomer, citrate salt) [ka]
[0153] To a solution of mirodenafil (500 mg, 0.940 mmol) and 4-nitrophenyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate (see Example 4) (423 mg, 1.128 mmol) in dry DCM (5 mL) was added DMAP (115 mg, 0.940 mmol).
[0154] The mixture was stirred at room temperature for 48 h and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.01% formic acid, 70:30 to 20:80).
[0155] After purification, the residue was added with DCM and a saturated solution of NaHCO3. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phase was dried over MgSO4 and concentrated under reduced pressure to give 540 mg of (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 3-(3-nitro-2-(nitrooxy)propoxy)propanoate (compound (1), yield: 75.0%).
[0156] Compound (1) (295 mg, 0.384 mmol) was redissolved in methanol (1.5 mL) and citric acid monohydrate (81 mg, 0.384 mmol) was added. The mixture was stirred at room temperature for 10 min, then concentrated and the solid was washed with diethyl ether. The solid was filtered and dried under reduced pressure to give the title compound (Compound (1)-(2S)-isomer, citrate salt) 361 mg (crude yield: 98%).
[0157] 1 H NMR (400 MHz, DMSO-d6) δ 2.30 (bs, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.80 (dd, J = 8.8, 2.5 Hz, 1H), 7.38 (d, J = 8.9 Hz, 1H), 7.31 (s, 1H), 5.53 m, J = 10.3, 6.7, 3.9 Hz, 1H), 4.88 (dd, J = 12.8, 3.0 Hz, 1H), 4.72 (dd, J = 12.9, 6.5 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 4.10 (dt, J = 11.4, 6.0 Hz, 4H), 3.77 - 3.58 (m, 4H), 2.90 (s, 4H), 2.75 (d, J = 15.4 Hz, 2H), 2.65 (d, J = 15.4 Hz, 2H), 2.61 - 2.52 (m, 10H), 1.80 - 1.58 (m, 4H), 1.36 (t, J = 7.1 Hz, 3H), 0.97 (t, 3H), 0.94 (t, 3H).
[0158] Example 10 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexanoate citrate (citrate of compound (4)) [ka]
[0159] To a solution of mirodenafil (500 mg, 0.940 mmol) in dry DCM (5 mL) was added DMAP (115 mg, 0.940 mmol), DCC (233 mg, 1.128 mmol) and 6-(nitrooxy)hexanoic acid (200 mg, 1.128 mmol).
[0160] The mixture was stirred at room temperature overnight and diluted with DCM and water. The two phases were separated and the aqueous layer was extracted twice with DCM. The combined organic extracts were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.1% formic acid, 70:30 to 20:80).
[0161] After purification, the residue was added with DCM and a saturated solution of NaHCO3. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phase was dried over MgSO4 and concentrated under reduced pressure to give 450 mg of 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexanoate (compound (4), yield: 69.0%).
[0162] To a solution of compound (4) (200 mg, 0.290 mmol) in methanol (1.5 mL) was added citric acid monohydrate (61 mg, 0.290 mmol). The mixture was stirred at room temperature for 10 min, then concentrated, and the solid was washed with diethyl ether. The solid was filtered and dried under reduced pressure to give the title compound (citrate salt of compound (4)) 253 mg (yield: 98.8%).
[0163] 1H NMR (400 MHz, DMSO-d6) δ 11.67 (s, 1H), 7.90 (d, J = 2.4 Hz, 1H), 7.80 (dd, J = 8.8, 2.5 Hz, 1H), 7.38 (d, J = 8.9 Hz, 1H), 7.31 (s, 1H), 4.47 - 4.32 (m, 4H), 4.09 (dt, J = 11.3, 6.0 Hz, 4H), 2.90 (s, 4H), 2.75 (d, J = 15.4 Hz, 2H), 2.65 (d, J = 15.4 Hz, 2H), 2.55 (ddd, J = 11.8, 8.4, 4.7Hz, 8H), 2.26 (t, J = 7.3 Hz, 2H), 1.81 - 1.69 (m, 2H), 1.69 - 1.55 (m, 4H), 1.50 (m, 2H), 1.39 - 1.33 (m, 3H), 1.29 (q, 2H), 0.94 (m, 6H).
[0164] Example 11 2-Hydroxypropane-1,2,3-tricarboxylic acid 2-{4-[3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxybenzene-1-sulfonyl]piperazin-1-yl}ethyl[2-(nitrooxy)ethoxy]acetate (citrate salt of compound (2)) [ka]
[0165] To a solution of mirodenafil (500 mg, 0.940 mmol) in dry DCM (5 mL) was added DMAP (115 mg, 0.940 mmol), DCC (233 mg, 1.128 mmol) and [2-(nitrooxy)ethoxy]acetic acid (186 mg, 1.128 mmol).
[0166] The mixture was stirred at room temperature for 48 h and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.1% formic acid, 70:30 to 40:60).
[0167] After purification, the residue was added with DCM and a saturated solution of NaHCO3. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phase was dried over MgSO4 and concentrated under reduced pressure to give 338 mg of 2-{4-[3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxybenzene-1-sulfonyl]piperazin-1-yl}ethyl[2-(nitrooxy)ethoxy]acetate (compound (2), yield: 53.0%).
[0168] To a solution of compound (2) (172 mg, 0.253 mmol) in methanol (1.5 mL) was added citric acid monohydrate (53 mg, 0.276 mmol). The mixture was stirred at room temperature for 10 min, then concentrated, and the solid was washed with diethyl ether. The solid was filtered and dried under reduced pressure to give the title compound (compound (2) citrate salt) 220 mg (crude yield: 99.8%).
[0169] 1H NMR (400 MHz, DMSO-d6) δ 11.68 (s, 1H), 7.90 (t, J = 5.8 Hz, 1H), 7.80 (m, 1H), 7.38 (d, J = 8.9 Hz, 1H), 7.31 (s, 1H), 4.67 - 4.59 (m, 2H), 4.45 - 4.27 (m, 2H), 4.20 - 4.04 (m, 6H), 3.78 - 3.71 (q, 2H), 2.90 (s, 4H), 2.75 (t, J = 15.4 Hz, 2H), 2.65 (t, J = 15.4 Hz, 2H), 2.61 - 2.52 (m, 8H), 1.81 - 1.55 (m, 4H), 1.36 (t, J = 7.1 Hz, 3H), 0.94 (t, 6H).
[0170] Example 12 (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 5,6-bis(nitrooxy)hexanoate citrate (compound (3)-(5S) isomer, citrate salt) [ka]
[0171] To a solution of mirodenafil (500 mg, 0.940 mmol) in dry DCM (5 mL) was added DMAP (115 mg, 0.940 mmol), DCC (233 mg, 1.128 mmol) and (5S)-5,6-bis(nitrooxy)hexanoic acid (270 mg, 1.128 mmol).
[0172] The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.1% formic acid, 70:30 to 40:60).
[0173] After purification, the residue was added with DCM and a saturated solution of NaHCO3. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phase was dried over MgSO4 and concentrated under reduced pressure to give 550 mg of (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 5,6-bis(nitrooxy)hexanoate (compound (3), yield: 77.8%).
[0174] To a solution of compound (3) (207 mg, 0.275 mmol) in methanol (1.5 mL) was added citric acid monohydrate (58 mg, 0.302 mmol). The mixture was stirred at room temperature for 10 min, then concentrated, and the solid was washed with diethyl ether. The solid was filtered and dried under reduced pressure to give the title compound (compound (3)-(5S) isomer, citrate salt) 254 mg (yield: 97.8%).
[0175] 1 H NMR (400 MHz, DMSO-d6) δ 11.67 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.80 (dd, J = 8.8, 2.5 Hz, 1H), 7.38 (d, J = 8.9 Hz, 1H), 7.31 (s, 1H), 5.38 (m, J = 13.1, 5.9, 2.6 Hz, 1H), 4.89 (dd, J = 12.9, 2.6 Hz, 2H), 4.70 (m, , 2H), 4.37 (q, J = 7.1 Hz, 2H), 4.09 (dt, J = 11.3, 6.0 Hz, 4H), 2.90 (s, 4H), 2.75 (t, 2H), 2.65 (d, J = 15.4 Hz, 2H), 2.61 - 2.52 (m, 8H), 2.32 (t, J = 7.1 Hz, 2H), 1.82 - 1.55 (m, 8H), 1.36 (t, J = 7.1 Hz, 3H), 0.94 (t, 6H).
[0176] Example 13 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexyl carbonate (compound (5)) [ka]
[0177] Step 1: 2-(4-((3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl)sulfonyl)piperazin-1-yl)ethyl (4-nitrophenyl) carbonate
[0178] To a solution of mirodenafil (290 mg, 0.545 mmol) in dry DCM (5 mL) was added nitrophenyl chloroformate (121 mg, 0.600 mmol) and DMAP (74 mg, 0.600 mmol). The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (cyclohexane: EtOAc: MeOH 5: 5: 0.1). The fractions were then collected and dried under reduced pressure to give 310 mg (yield: 81.7%) of the title compound (2-(4-((3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl)sulfonyl)piperazin-1-yl)ethyl (4-nitrophenyl) carbonate) as a colorless oil.
[0179] Step 2: 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexyl carbonate
[0180] To a solution of 2-(4-((3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl)sulfonyl)piperazin-1-yl)ethyl (4-nitrophenyl) carbonate (150 mg, 0.21 mmol) in dry DCM (1 mL) was added DMAP (30 mg, 0.24 mmol) and 6-hydroxyhexyl nitrate (39 mg, 0.24 mmol). The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN with 0.1% formic acid, 90:10 to 20:80). The residue after purification was added with dichloromethane and a saturated solution of NaHCO3. The two phases were separated and the aqueous phase was extracted twice with DCM. The fractions were then collected and dried under reduced pressure to give the title compound (compound (5)) 150 mg (yield: 97%) as a sticky oil.
[0181] 1 H NMR (600 MHz, DMSO-d6) δ 11.65 (s, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.80 (dd, J = 8.8, 2.4 Hz, 1H), 7.38 (d, J = 8.9 Hz, 1H), 7.31 (s, 1H), 4.47 (t, J = 6.6 Hz, 2H), 4.37 (q, J = 7.1 Hz, 2H), 4.13 (t, J = 5.9 Hz, 2H), 4.00 (t, J = 6.6 Hz, 2H), 2.88 (t, 2H), 2.60 - 2.51 (m, 8H), 1.79 - 1.70 (m, 2H), 1.68 - 1.57 (m, 4H), 1.56 - 1.48 (m, 2H), 1.36 (t, J = 7.2 Hz, 3H), 1.33 - 1.22 (m, 4H), 0.97 (t, J = 7.4 Hz, 3H), 0.92 (t, J = 7.3 Hz, 3H).
[0182] Example 14 (S)-5,6-Bis(nitrooxy)hexyl 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl) carbonate (compound (6)) [ka]
[0183] To a solution of 2-(4-((3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl)sulfonyl)piperazin-1-yl)ethyl (4-nitrophenyl) carbonate, prepared as described in Example 13, step 1, in dry DCM (2 mL) was added DMAP (39 mg, 0.32 mmol) and 6-hydroxyhexane-1,2-diyl dinitrate (72 mg, 0.32 mmol).
[0184] The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phase was dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN, 85:15 to 20:80 with 0.1% formic acid). Dichloromethane and a saturated solution of NaHCO3 were added to the residue after purification. The two phases were separated and the aqueous phase was extracted twice with DCM. The fractions were then collected and dried under reduced pressure to give the desired product (compound (6)) 150 mg (yield: 73.5%) as a sticky oil.
[0185] 1H NMR (400 MHz, DMSO-d6) δ 11.66 (s, 1H), 7.88 (d, J = 2.4 Hz, 1H), 7.80 (dd, J = 8.8, 2.5 Hz, 1H), 7.38 (d, J = 8.9 Hz, 1H), 7.31 (s, 1H), 5.38 (dt, J = 6.2, 4.3 Hz, 1H), 4.90 (dd, J = 12.9, 2.6 Hz, 1H), 4.67 (dd, J = 12.9, 6.1 Hz, 1H), 4.37 (q, J = 7.2 Hz, 2H), 4.20 - 3.96 (m, 6H), 2.75 (m, 6H), 2.62 - 2.51 (m, 8H), 1.82 - 1.52 (m, 8H), 1.46 - 1.29 (m, 3H), 0.94 (t, J = 7.4 Hz, 6H).
[0186] Example 15 (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexyl carbonate (compound (13)) [ka]
[0187] Step 1: (S)-(1-(4-((3-chloro-4-methoxybenzyl)amino)-5-((pyrimidin-2-ylmethyl)carbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (4-nitrophenyl) carbonate
[0188] To a solution of avanafil (500 mg, 1.033 mmol) in dry DCM (10 mL) was added 4-nitrophenyl chloroformate (416 mg, 2.066 mmol) and pyridine (184 μL, 2.346 mmol). The mixture was stirred at room temperature for 2 h and then diluted with DCM and water. The two phases were separated and the aqueous layer was extracted twice with DCM to give the desired product ((S)-(1-(4-((3-chloro-4-methoxybenzyl)amino)-5-((pyrimidin-2-ylmethyl)carbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (4-nitrophenyl) carbonate) 1.02 g.
[0189] Step 2: (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexyl carbonate
[0190] To a solution of (S)-(1-(4-((3-chloro-4-methoxybenzyl)amino)-5-((pyrimidin-2-ylmethyl)carbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (4-nitrophenyl) carbonate (1.02 g, 1.57 mmol) in dry DCM (20 mL) was added DMAP (211 mg, 1.73 mmol) and 6-hydroxyhexyl nitrate (282 mg, 1.73 mmol). The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / iPrOH 100:0 to 90:10). The fractions were then collected and dried under reduced pressure to give the title compound (Compound (13)) 405 mg (yield: 38%) as a sticky oil.
[0191] 1H NMR (600 MHz, DMSO-d6) δ 9.17 (t, J = 6.0 Hz, 1H), 8.79 (m, 1H), 8.75 (d, J = 4.9 Hz, 2H), 8.55 (m, 1H), 7.45 - 7.15 (m, 3H), 7.04 (d, J = 8.3 Hz, 1H), 4.61 - 4.43 (m, 6H), 4.29 (m, 3H), 4.05 (t, J = 6.4 Hz, 2H), 3.81 (s, 3H), 3.56 - 3.42 (m, 2H), 2.05 - 1.80 (m, 4H), 1.60 (m, 4H), 1.32 (t, 4H).
[0192] Example 16 (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 3-(2,3-bis(nitrooxy)propoxy)propanoate dihydrochloride (compound (1)-(2S)) [ka]
[0193] To a solution of compound (1) (72 mg, 0.094 mmol) obtained in Example 9 in methanol (1.0 mL) was added a 3M solution of HCl in methanol (63 μL, 0.188 mmol). The mixture was stirred at room temperature for 10 minutes, then concentrated, and the solid was washed with Et2O. The solid was filtered and dried under reduced pressure to give the title compound (compound (1)-(2S) dihydrochloride salt) 68 mg (yield: 86%).
[0194] 1H NMR (600 MHz, DMSO-d6) δ 11.73 (s, 1H), 11.05 (s, 1H), 8.07 - 7.76 (m, 2H), 7.42 (d, J = 8.7 Hz, 1H), 7.32 (s, 1H), 5.59 - 5.52 (m, 1H), 4.90 (dd, J = 12.8, 2.8 Hz, 1H), 4.75 (dd, J = 12.8, 6.5 Hz, 1H), 4.38 (q, J = 7.1 Hz, 3H), 4.14 (t, J = 6.3 Hz, 2H), 3.77-3.66 (m, 6H), 2.60-2.49 (m, 14H), 1.80 - 1.72 (m, 2H), 1.69 - 1.60 (m, 2H), 1.36 (t, J = 7.2 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H), 0.93 (t, J = 7.3 Hz, 3H).
[0195] Example 17 ((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (S)-5,6-bis(nitrooxy)hexyl carbonate (compound (14)-(5S) isomer) [ka]
[0196] To a solution of (s)-(1-(4-((3-chloro-4-methoxybenzyl)amino)-5-((pyrimidin-2-ylmethyl)carbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (4-nitrophenyl) carbonate (prepared as described in Example 15, step 1) (758 mg, 1.167 mmol) in dry DCM (10 mL) was added DMAP (157 mg, 1.284 mmol) and (2S)-6-hydroxyhexane-1,2-diyldinitrate (288 mg, 1.284 mmol).
[0197] The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous layer was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / iPrOH, 100:0 to 90:10) and then reverse phase chromatography (H2O / CH3CN, 100:0 to 0:100) to give the desired product (compound (14)-(5S) isomer) 334 mg (yield: 39%) as a sticky solid.
[0198] 1 H NMR (600 MHz, DMSO-d6) δ 9.17 (d, J = 5.5 Hz, 1H), 8.79 (m, 1H), 8.75 (d, J = 4.9 Hz, 2H), 8.55 (s, 1H), 7.44 - 7.16 (m, 3H), 7.04 (d, J = 7.7 Hz, 1H), 5.41 (m, 1H), 4.92 (d, J = 12.8 Hz, 1H), 4.69 (dd, J = 12.7, 6.0 Hz, 1H), 4.64 - 4.42 (m, 4H), 4.39 - 4.14 (m, 3H), 4.06 (m, 2H), 3.81 (m, 3H), 3.49 (m, 2H), 1.92 (m, 4H), 1.66 (m, 4H), 1.42 (m, 2H).
[0199] Example 18 (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexyl carbonate 2-hydroxypropane-1,2,3-tricarboxylate (compound (13) citrate salt) [ka]
[0200] To a solution of (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexyl carbonate (compound (13) prepared as described in Example 15) (218 mg, 0.324 mmol) in methanol (1.0 mL) was added citric acid monohydrate (68 mg, 0.324 mmol). The mixture was stirred at room temperature for 10 minutes, then concentrated, and the solid was washed with MTBE. The solid was filtered and dried under reduced pressure to give the desired product (citrate salt of compound (13)) 265 mg (crude yield: 94.5%).
[0201] 1 H NMR (400 MHz, DMSO-d6) δ 9.19 (t, J = 5.8 Hz, 1H), 8.80 (m, 1H), 8.75 (d, J = 4.9 Hz, 2H), 8.54 (m, 1H), 7.38 (t, J = 4.9 Hz, 1H), 7.35 - 7.15 (m, 2H), 7.06 (s, 1H), 4.64 - 4.43 (m, 6H), 4.29 (m, 3H), 4.05 (t, J = 6.5 Hz, 2H), 3.81 (s, 3H), 3.49 (t, J = 7.1 Hz, 2H), 2.76 (d, J = 15.4 Hz, 2H), 2.65 (d, J = 15.4 Hz, 2H), 2.06 - 1.81 (m, 4H), 1.61 (m, 4H), 1.33 (m, 4H).
[0202] Example 19 2-{4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzene-1-sulfonyl]piperazin-1-yl}ethyl 6-(nitrooxy)hexanoate (compound (8b)) [ka]
[0203] To a solution of lodenafil (400 mg, 0.793 mmol) in dry DCM (5 mL) was added DMAP (97 mg, 0.793 mmol), DCC (196 mg, 0.951 mmol) and 6-(nitrooxy)hexanoic acid (168 mg, 0.951 mmol).
[0204] The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN, 90:10 to 20:80 with 0.01% formic acid). Dichloromethane and a saturated solution of NaHCO3 were added to the purified residue. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure to give the desired product (compound (8b)) 150 mg (yield: 69.0%).
[0205] 1 H NMR (400 MHz, DMSO-d6) δ 12.17 (s, 1H), 7.81 (m, 2H), 7.36 (d, J = 8.7 Hz, 1H), 4.43 (t, J = 6.6 Hz, 2H), 4.19 (q, J = 6.9 Hz, 2H), 4.14 (s, 3H), 4.03 (t, J = 5.7 Hz, 2H), 2.86 (bs, 4H), 2.75 (t, J = 7.5 Hz, 2H), 2.58 - 2.37 (m, 5H), 2.23 (t, J= 7.3 Hz, 2H), 1.72 (dd, J = 14.9, 7.4 Hz, 2H), 1.63 - 1.53 (m, 2H), 1.53 - 1.40 (m, 2H), 1.35 - 1.20 (m, 6H), 0.92 (t, J = 7.4 Hz, 3H).
[0206] Example 20 (S)-2-(4-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl (S)-5,6-bis(nitrooxy)hexanoate (compound (7b)-(5S) isomer) [ka]
[0207] To a solution of lodenafil (400 mg, 0.793 mmol) in dry DCM (5 mL) were added DMAP (97 mg, 0.793 mmol), DCC (196 mg, 0.951 mmol) and (5S)-5,6-bis(nitrooxy)hexanoic acid (226 mg, 0.951 mmol). The mixture was stirred at room temperature overnight and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN, 85:15 to 10:90 with 0.01% formic acid). Dichloromethane and a saturated solution of NaHCO3 were added to the residue after purification. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phase was dried over MgSO4 and concentrated under reduced pressure to give the desired product (compound (7b)-(5S) isomer) 150 mg (yield: 78.0%).
[0208] 1H NMR (400 MHz, DMSO-d6) δ 12.17 (s, 1H), δ 7.85 - 7.76 (m, 2H), 7.36 (d, J = 8.7 Hz, 1H), 5.36 (m, J = 6.0, 3.4 Hz, 1H), 4.87 (dd, J = 12.9, 2.6 Hz, 1H), 4.65 (dd, J = 12.9, 5.9 Hz, 1H), 4.26 - 4.12 (m, 5H), 4.02 (t, J= 5.7 Hz, 2H), 2.87 (bs, 4H), 2.75 (t, J= 7.6 Hz, 2H), 2.59 - 2.41 (m, 3H), 2.30 (t, J = 7.1 Hz, 2H), 2.08 (s, 2H), 1.78 - 1.33 (m, 7H), 1.32 (t, J = 6.9 Hz, 3H), 0.92 (t, J = 7.4 H).
[0209] Example 21 - (Comparative) - Nitrate Esters of PDE5 Inhibitors 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl nitrate [ka]
[0210] The nitrate ester of mirodenafil was prepared from mirodenafil according to the procedure described in WO 2017 / 085056 (Example 29): the hydroxyl group of mirodenafil was first converted to the corresponding bromide using a known method (PPh3 / NBS) and then nitrated with silver nitrate in acetonitrile.
[0211] 1H NMR (600 MHz, CHLOROFORM-d) δ ppm 10.71 (br s, 1 H) 7.80 (dd, J=8.65, 2.49 Hz, 1 H) 7.15 (d, J=8.80 Hz, 1 H) 5.30 (s, 1 H) 4.41 - 4.55 (m, 5 H) 4.25 (t, J=6.45 Hz, 3 H) 3.11 (br s, 5 H) 2.72 (t, J=7.48 Hz, 4 H) 2.53 - 2.69 (m, 5 H) 2.00 - 2.09 (m, 3 H) 1.74 (sxt, J=7.39 Hz, 4 H) 1.48 (t, J=7.19 Hz, 5 H) 1.20 (t, J=7.33 Hz, 5 H) 1.00 (t, J=7.33 Hz, 5 H).
[0212] Example 22 Effect of lowering intraocular pressure (IOP) in non-human primates with laser-induced ocular hypertension
[0213] In this study, the efficacy of the compound of formula (Ia), compound (1)-(2S)-citrate (disclosed in Example 9), the NO-donor 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid ((IIIg)-OH) and a reference PDE5 inhibitor, mirodenafil, in reducing intraocular pressure was evaluated in non-human primates with laser-induced ocular hypertension.
[0214] Experimental procedure Compound (1)-(2S)-citrate (0.48 μmol / eye: equivalent to 1.59% weight / volume, 30 μL), mirodenafil (0.48 μmol / eye: equivalent to 1% weight / volume, 30 μL), NO-donor ((IIIg)-OH=3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid; 1.17 μmol / eye: equivalent to 1% weight / volume, 30 μL) or vehicle (phosphate buffer pH 6, Cremophor EL 5% weight / volume, DMSO 0.3% weight / volume, benzalkonium chloride 0.02% weight / volume) were administered in a masked fashion to non-human primates with laser-induced ocular hypertension. The contralateral eye was not treated.
[0215] Intraocular pressure was measured using a pneumatonometer (Model 30™ Reichert, Depew, NY, USA) at selected time points before (baseline) and after ocular administration. One drop of proparacaine hydrochloride 0.13% was instilled topically into the eye prior to each intraocular pressure measurement.
[0216] result Data are reported as mean ± SEM of n=13. Efficacy (E) as IOP change was calculated using the following formula: (IOP 薬物 -IOP 薬物の基底 )-(IOP ベヒクル -IOP ベヒクルの基底 ) The values reported were calculated relative to baseline and vehicle values using the maximal IOP change (E max ) and the effect of lowering IOP detected 300 minutes after administration (E 300分 )
[0217] The results demonstrated that the nitric oxide releasing phosphodiesterase type 5 inhibitor of the present invention (compound (1)-(2S)-citrate) exhibited a higher maximum intraocular pressure lowering effect (Emax) and a longer duration than a single dose of compound (IIIg)-OH (NO-donor) and mirodenafil (reference PDE5 inhibitor). Of note, the NO-donor (IIIg-OH) was administered at a dose 2.4 times higher than that of the compound of the present invention ((1)-(2S)-citrate).
[0218] [Table 1]
[0219] Example 23 Effect of lowering intraocular pressure (IOP) in non-human primates with laser-induced ocular hypertension
[0220] In an independent experiment, the efficacy of the compound of formula (II), compound (9)-citrate (disclosed in Example 5), and the NO-donor 6-(nitrooxy)hexanoic acid ((IIIa)-OH), in reducing intraocular pressure was evaluated in non-human primates with laser-induced ocular hypertension.
[0221] Experimental procedure Compound (9)-citrate (0.79 μmol / eye: equivalent to 2.2% weight / volume, 30 μL) or NO-donor ((IIIa)-OH=6-(nitrooxy)hexanoic acid (0.79 μmol / eye: equivalent to 0.47% weight / volume, 30 μL) or vehicle (phosphate buffer pH 6, Cremophor EL 5% weight / volume, DMSO 0.3% weight / volume, benzalkonium chloride 0.02% weight / volume) were administered to non-human primates with laser-induced ocular hypertension. The contralateral eye was not treated.
[0222] Intraocular pressure was measured before (baseline) and at selected time points after ocular administration using a pneumatonometer (Model 30™ Reichert, Depew, NY, USA). One drop of proparacaine hydrochloride 0.13% was instilled topically into the eye prior to each intraocular pressure measurement.
[0223] result Efficacy (E) as IOP change was calculated using the following formula: (IOP 薬物 -IOP 薬物の基底 )-(IOP ベヒクル -IOP ベヒクルの基底 ) were used to calculate relative to baseline and vehicle values (IOP values taken at 30, 60, 180, 300 and 480 minutes after administration).
[0224] The results reported in Table 2 show that the nitric oxide releasing phosphodiesterase type 5 inhibitor of the present invention (compound (9)-citrate) exhibited a higher maximum intraocular pressure lowering effect (E of compound (IIIa)-OH at 60 minutes). max -5.2±1.0 mmHg, E of compound (9)-citrate at 480 minutes max -6.0±2.1 mmHg) and shows a longer duration (E 480 , -2.7 ± 1.5 mmHg, and the E of compound (9)-citrate at the same time point. 480 , -6.0±2.1mmHg).
[0225] [Table 2]
[0226] Data reported are the mean ± SEM of three independent experiments with n = 8 eyes each for compound 6-(nitrooxy)hexanoic acid ((IIIa)-OH) and the mean ± SEM of one experiment with n = 8 eyes for compound (9)-citrate.
[0227] Example 24 Intraocular pressure (IOP) lowering effect in normotensive New Zealand White rabbits
[0228] In this study, the efficacy of the compound 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid ((IIIg)-OH) (disclosed in Example 4), a NO-donor and a reference PDE5 inhibitor (mirodenafil), in reducing intraocular pressure was evaluated in normotensive New Zealand White rabbits.
[0229] Experimental procedure Male New Zealand White (NZW) rabbits were topically administered vehicle (phosphate buffer pH 6.0, Cremophor EL 5% wt / vol, DMSO 0.3% wt / vol, benzalkonium chloride 0.02% wt / vol) (50 μL), 0.5 μmol / eye (equivalent to 0.63% wt / vol) mirodenafil (50 μL volume), or 0.5 μmol / eye (equivalent to 0.26% wt / vol) Compound (IIIg-OH) (50 μL volume, alone or in combination with 0.5 μmol / eye mirodenafil (50 μL volume)).
[0230] Intraocular pressure was measured before (basal) and at selected time points after ocular administration using a pneumatonometer (Model 30™ Reichert, Depew, NY, USA). Prior to each intraocular pressure measurement, one drop of NOVESINA 0.4% (purchased from Thea Pharma) was instilled topically into the eye.
[0231] result Data are expressed as mean ± SEM of n = 6 to 9. Efficacy (E) as change in intraocular pressure (IOP) was calculated using the following formula: (IOP 薬物 -IOP 薬物の基底 )-(IOP ベヒクル -IOP ベヒクルの基底 ) were used to calculate relative to basal and vehicle values.
[0232] IOP values are taken at peak effect and 300 minutes after administration.
[0233] The results reported in Table 3 show that the combined instillation of mirodenafil (reference PDE5 inhibitor) and the compound (3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid ((IIIg)-OH)) did not show any improvement in the effect of lowering intraocular pressure compared to the administration of each compound alone, and in fact, the efficacy (E max ) demonstrated comparable efficacy to the instillation of a combination of mirodenafil and Compound (IIIg)-OH.
[0234] [Table 3]
[0235] Example 25 Intraocular pressure (IOP) lowering effect in normotensive New Zealand White rabbits
[0236] In this study, the efficacy of the compound of the present invention (1)-(2S)-citrate (disclosed in Example 9), i.e., an NO-releasing derivative of mirodenafil, and mirodenafil nitrate (PDE5-nitrate disclosed in Comparative Example 21), in which a nitrooxy group (ONO2) is directly attached to the hydroxyl group of the mirodenafil molecule, in reducing intraocular pressure was evaluated in normotensive New Zealand White rabbits.
[0237] Experimental procedure Male New Zealand White (NZW) rabbits were topically administered vehicle (phosphate buffer pH 6.0, Cremophor EL 5% wt / vol, DMSO 0.3% wt / vol, benzalkonium chloride 0.02% wt / vol) (50 μL), 0.5 μmol / eye (equivalent to 1% wt / vol) of (1)-(2S)-citrate (50 μL volume), or 0.5 μmol / eye (equivalent to 0.6% wt / vol) of PDE5 nitrate (50 μL volume).
[0238] Intraocular pressure was measured before (basal) and at selected time points after ocular administration using a pneumatonometer (Model 30™ Reichert, Depew, NY, USA). Prior to each intraocular pressure measurement, one drop of NOVESINA 0.4% (purchased from Thea Pharma) was instilled topically into the eye.
[0239] result Data are expressed as mean ± SEM of n = 6 to 9. Efficacy (E) as change in intraocular pressure (IOP) was calculated as follows: (IOP 薬物 -IOP 薬物の基底 )-(IOP ベヒクル -IOP ベヒクルの基底 ) The values were calculated relative to basal and vehicle values as follows: IOP values are taken at 30, 60, and 180 minutes after administration.
[0240] The results reported in Table 4 show that the nitric oxide-releasing phosphodiesterase type 5 inhibitor of the present invention (compound (1)-(2S)-citrate) exhibits a higher intraocular pressure lowering effect (E of compound (1)-(2S)-citrate) max of the corresponding PDE5 nitrate max (compared to PDE5 nitrate) and exhibited a longer duration of effect (180 minute IOP change for compound (1)-(2S)-citrate compared to that for PDE5 nitrate).
[0241] [Table 4]
[0242] Example 26 Effect of lowering intraocular pressure (IOP) in non-human primates with laser-induced ocular hypertension
[0243] In this experiment, the effectiveness of compound of formula (II), Compound (9)-fumarate salt (disclosed in Example 29), in reducing intraocular pressure was evaluated in non-human primates with laser-induced ocular hypertension.
[0244] Experimental procedure Compound (9)-fumarate (2.0% w / v, 30 μL) or vehicle (phosphate buffer pH 6, Cremophor EL 5% w / v, DMSO 0.3% w / v, benzalkonium chloride 0.02% w / v) was administered to non-human primates with laser-induced ocular hypertension. The contralateral eye was left untreated.
[0245] Intraocular pressure was measured before (basal) and at selected time points after ocular administration using a pneumatonometer (Model 30™ Reichert, Depew, NY, USA). Prior to each intraocular pressure measurement, one drop of proparacaine hydrochloride 0.13% was instilled topically into the eye.
[0246] result Efficacy (E) as IOP change was calculated using the following formula: (IOP 薬物 -IOP 薬物の基底 )-(IOP ベヒクル -IOP ベヒクルの基底 ) were used to calculate relative to baseline and vehicle values (IOP values taken at 30, 60, 300, 480 and 1440 minutes post-dose).
[0247] The results reported in Table 5 show that compound (9)-fumarate had a maximum intraocular pressure lowering effect (E max Furthermore, the IOP-lowering effect of compound (9)-fumarate continued up to 24 hours after administration, and the change in intraocular pressure at that time was still -2.8±2.0 mmHg.
[0248] [Table 5] Data reported are the mean ± SEM of one experiment performed with n = 8 eyes.
[0249] Example 27 Effect of lowering intraocular pressure (IOP) in non-human primates with laser-induced ocular hypertension
[0250] In this study, the efficacy of compound (1)-(2S)-citrate (disclosed in Example 9), the NO-donor 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid (compound (IIIg)-OH, disclosed in Example 4), the reference PDE5 inhibitor mirodenafil, and the combined administration of mirodenafil and the NO-donor 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoic acid in reducing intraocular pressure was evaluated in non-human primates with laser-induced ocular hypertension.
[0251] Experimental procedure Compound (1)-(2S)-citrate (0.31 μmol / eye: equivalent to 1.0% w / v, 30 μL), mirodenafil (0.31 μmol / eye: equivalent to 0.63% w / v, 30 μL), (IIIg)-OH (0.31 μmol / eye: equivalent to 0.26% w / v, 30 μL), mirodenafil with (IIIg)-OH administered simultaneously, or vehicle (phosphate buffer pH 6, Cremophor EL 5% w / v, DMSO 0.3% w / v, benzalkonium chloride 0.02% w / v) were administered in a blinded manner to non-human primates with laser-induced ocular hypertension. The contralateral eye was not treated.
[0252] Intraocular pressure was measured using a pneumatonometer (Model 30™ Reichert, Depew, NY, USA) at selected time points before (baseline) and after ocular administration. Prior to each intraocular pressure measurement, one drop of proparacaine hydrochloride 0.13% was instilled topically into the eye.
[0253] result Data are reported as mean ± SEM of n = 13. Efficacy (E) as change in IOP was calculated using the following formula: (IOP 薬物 -IOP 薬物基底 )-(IOP ベヒクル -IOP ベヒクル基底 ) were used to calculate relative to basal and vehicle values. The reported values are maximum IOP changes (E max ) and the IOP lowering effect detected 300 minutes after administration (E 300分 )
[0254] The results reported in Table 6 demonstrate that the nitric oxide releasing phosphodiesterase type 5 inhibitor of the present invention (compound (1)-(2S)-citrate) exhibits a greater intraocular pressure lowering effect than equimolar doses of NO-donor ((IIIg)-OH), mirodenafil, or a combination of mirodenafil and NO-donor at most of the time points analyzed.
[0255] [Table 6]
[0256] Example 28 (S)-2-(4-((4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)sulfonyl)piperazin-1-yl)ethyl-(S)-3-(2,3-bis(nitrooxy)propoxy)propanoate (compound (15), (S) isomer) [ka]
[0257] To a solution of lodenafil (400 mg, 0.794 mmol) and 4-nitrophenyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate (see Example 4) (226 mg, 0.951 mmol) in dry DCM (5 mL) was added DMAP (97 mg, 0.794 mmol).
[0258] The mixture was stirred at room temperature over the weekend and then diluted with DCM and water. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The residue was purified by reverse phase chromatography (H2O / CH3CN, 80:20 to 20:80 with 0.01% formic acid). Dichloromethane and a saturated solution of NaHCO3 were added to the purified residue. The two phases were separated and the aqueous phase was extracted twice with DCM. The combined organic phases were dried over MgSO4 and concentrated under reduced pressure to give 170 mg of the desired product (compound (15), (S) isomer) (yield: 30.0%).
[0259] 1 H NMR (600 MHz, dmso) δ 12.19 (s, 1H), 7.83 (dt, J = 8.7, 2.4 Hz, 2H), 7.38 (d, J = 8.8 Hz, 1H), 5.53 (m, 1H), 4.88 (dd, J = 12.8, 3.0 Hz, 1H), 4.72 (dd, J = 12.8, 6.5 Hz, 1H), 4.21 (q, 2H), 4.16 (s, 3H), 4.06 (t, 2H), 3.77 - 3.59 (m, 4H), 2.89 (bs, 4H), 2.77 (t, 2H), 2.55 (m, 8H), 1.74 (dd, J = 14.9, 7.4 Hz, 2H), 1.33 (t, J = 6.9 Hz, 3H), 0.94 (t, J= 7.4 Hz, 3H).
[0260] Example 29 (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate fumarate (compound (9) fumarate) [ka]
[0261] To a solution of compound (9) (100 mg, 0.155 mmol) prepared as described in Example 1 in methanol (1.5 mL) was added fumaric acid (18 mg, 0.155 mmol). The mixture was stirred at room temperature for 10 minutes, then concentrated and the solid was washed with MTBE. The solid was filtered and dried under reduced pressure to produce 103 mg of (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate fumarate (compound (9) fumarate, yield: 87%).
[0262] 1 H NMR (600 MHz, DMSO-d6) δ 13.13 (m, 2H), 9.17 (m, 1H), 8.76 (m, 3H), 8.54 (m, 1H), 7.38 (m, 1H), 7.24 (m, 2H), 7.04 (m, 1H), 6.63 (s, 2H), 4.52 (m, 5H), 4.20 (m, 2H), 3.81 (s, 3H), 3.52 (m, 2H), 3.32 (m, 2H), 2.31 (m, 2H), 1.92 (m, 4H), 1.64 (m, 2H), 1.50 (m, 2H), 1.32 (m, 2H).
[0263] Example 30 (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate maleate (compound (9) maleate) [ka]
[0264] To a solution of compound (9) (100 mg, 0.155 mmol) prepared as described in Example 1 in methanol (1.5 mL) was added maleic acid (18 mg, 0.155 mmol). The mixture was stirred at room temperature for 10 minutes, then concentrated and the solid was washed with MTBE. The solid was filtered and dried under reduced pressure to give 113 mg of (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-ylmethylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate 2-maleate (compound (9) maleate, yield: 96%).
[0265] 1 H NMR (600 MHz, DMSO-d6) δ 12.35 (m, 3H), 9.18 (m, 1H), 8.77 (m, 3H), 8.54 (s, 1H), 7.38 (m, 2H), 7.22 (m, 1H), 7.04 (m, 1H), 4.55 (m, 6H), 4.20 (m, 3H), 3.98 (m, 1H), 3.80 (s, 3H), 3.49 (m, 2H), 2.75 (m, 2H), 2.65 (m, 2H), 2.31 (m, 2H), 1.92 (m, 4H), 1.56 (m, 4H), 1.32 (m, 2H).
[0266] Example 31 Intraocular pressure (IOP) lowering effect in normotensive New Zealand White rabbits
[0267] In this study, the effectiveness of compound (12)-(2S)-citrate salt of the present invention (disclosed in Example 8) in reducing intraocular pressure was evaluated in normotensive New Zealand White rabbits.
[0268] Experimental procedure Male New Zealand White (NZW) rabbits were topically administered (50 μL) vehicle (phosphate buffer pH 6.0, Cremophor EL 5% w / v, DMSO 0.3% w / v, benzalkonium chloride 0.02% w / v) or (12)-(2S)-citrate at a concentration of 1%.
[0269] Intraocular pressure was measured before (basal) and at selected time points after ocular administration using a pneumatonometer (Model 30™ Reichert, Depew, NY, USA). Prior to each intraocular pressure measurement, one drop of NOVESINA 0.4% (purchased from Thea Pharma) was instilled topically into the eye.
[0270] result Data are expressed as mean ± SEM of n=9. Efficacy (E) as change in intraocular pressure (IOP) was calculated as follows: (IOP 薬物 -IOP 薬物の基底 )-(IOP ベヒクル -IOP ベヒクルの基底 ) IOP values are taken at 30, 60 and 120 minutes after dosing and are calculated relative to baseline and vehicle values as follows: The results reported in Table 7 demonstrated that the nitric oxide-releasing phosphodiesterase type 5 inhibitor of the present invention (compound (12)-(2S)-citrate salt) effectively reduced IOP at several time points following administration.
[0271] [Table 7]
Claims
1. Formula (I) or (II): [Formula 1] (In the formula, R 1 teeth, [Case 2] is selected from the group consisting of R 2 is n-propyl, R 3 is methyl) or a pharma- ceutically acceptable salt thereof.
2. 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 3-(2,3-bis(nitrooxy)propoxy)propanoate (compound (1)); 2-(4-((3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl)sulfonyl)piperazin-1-yl)ethyl 2-(2-(nitrooxy)ethoxy)acetate (compound (2)); 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 5,6-bis(nitrooxy)hexanoate (compound (3)); 2-(4-((3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl)sulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexanoate (compound (4)) 2. A compound of formula (I) according to claim 1, selected from the group consisting of:
3. (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-yl-methylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate (compound (9)); [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 5,6-bis(nitrooxy)hexanoate (compound (10)); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-yl-methylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 2-(2-(nitrooxy)ethoxy)acetate (compound (11)); [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 3-[2,3-bis(nitrooxy)propoxy]propanoate (compound (12)) 2. The compound of formula (II) according to claim 1, selected from the group consisting of:
4. [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl (5S)-5,6-bis(nitrooxy)hexanoate (compound (10)-(5S)); [(2S)-1-(4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-5-{[(pyrimidin-2-yl)methyl]carbamoyl}pyrimidin-2-yl)pyrrolidin-2-yl]methyl 3-[(2S)-2,3-bis(nitrooxy)propoxy]propanoate (compound (12)-(2S)); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-yl-methylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate 2-hydroxypropane-1,2,3-tricarboxylate (compound (9)-citrate salt); ((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-yl-methylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl (5S)-5,6-bis(nitrooxy)hexanoate 2-hydroxypropane-1,2,3-tricarboxylate (compound (10)-(5S) citrate salt); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-yl-methylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 2-(2-(nitrooxy)ethoxy)acetate 2-hydroxypropane-1,2,3-tricarboxylate (compound (11) citrate salt)); ((S)-1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-yl-methylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 3-((S)-2,3-bis(nitrooxy)propoxy)propanoate 2-hydroxypropane-1,2,3-tricarboxylate (compound (12)-(2S) citrate salt); (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 3-[2,3-bis-(nitrooxy)propoxy)]propanoate citrate (compound (1)-(2S) citrate); 2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 6-(nitrooxy)hexanoate citrate (compound (4) citrate); 2-Hydroxypropane-1,2,3-tricarboxylic acid 2-{4-[3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxybenzene-1-sulfonyl]piperazin-1-yl}ethyl [2-(nitrooxy)ethoxy]acetate (compound (2) citrate salt); (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 5,6-bis(nitrooxy)hexanoate citrate (compound (3)-(5S) citrate); (S)-2-(4-(3-(5-ethyl-4-oxo-7-propyl-4,5-dihydro-3H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenylsulfonyl)piperazin-1-yl)ethyl 3-(2,3-bis(nitrooxy)propoxy)propanoate dihydrochloride (compound (1)-(2S) hydrochloride); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-yl-methylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate fumarate (compound (9) fumarate); (S)-(1-(4-(3-chloro-4-methoxybenzylamino)-5-(pyrimidin-2-yl-methylcarbamoyl)pyrimidin-2-yl)pyrrolidin-2-yl)methyl 6-(nitrooxy)hexanoate maleate (compound (9) maleate) 2. The compound of formula (I) or (II) according to claim 1, selected from the group consisting of:
5. A pharmaceutical composition comprising a compound of formula (I) or formula (II) according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof.
6. 6. A pharmaceutical composition according to claim 5 for use in the treatment of a disease or condition associated with elevated intraocular pressure.
7. 7. The pharmaceutical composition according to claim 6, wherein the disease or condition is selected from ocular hypertension, glaucoma, open-angle glaucoma, normal tension glaucoma, pigmentary glaucoma, pseudoexfoliation glaucoma and drug-induced glaucoma.
8. 8. A pharmaceutical composition according to claim 7 for use in the treatment of retinopathy, including retinopathy of prematurity, retinal vein occlusion or diabetic macular oedema.
9. An ophthalmic pharmaceutical composition comprising a compound of formula (I) or formula (II) according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof.
Citation Information
Patent Citations
Nitric oxide donating derivatives of prostaglandins
EP3088388A1
Nitric oxide donor compounds
JP2011511022A
Combination of prostaglandin and nitric oxide donor
JP2017534658A
Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
US20020168424A1
Nitric oxide donating derivatives of fluprostenol
WO2016155906A1
Cited By
Compositions for the treatment of glaucoma and ocular hypertension
JP2023516891A
